You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
M 30 dihydrochloride
Potent and brain selective monoamine oxidase (MAO) inhibitor (EC50 values are 37 and 57 nM for MAO-A and MAO-B, respectively). Also an iron chelator with antioxidant properties. Protects cells against 6-OHDA (Cat. No. 2547) induced apoptosis. Attenuates MPTP depletion of DA and increases striatal monoamine levels in a mouse Parkinson's disease model.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 299.2. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.34 mL||16.71 mL||33.42 mL|
|5 mM||0.67 mL||3.34 mL||6.68 mL|
|10 mM||0.33 mL||1.67 mL||3.34 mL|
|50 mM||0.07 mL||0.33 mL||0.67 mL|
References are publications that support the biological activity of the product.
Zheng et al (2005) Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central nervous system neurons. Biochem.Pharmacol. 70 1642 PMID: 16226724
Zheng (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J.Neurochem. 95 68 PMID: 16181413
Gal et al (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal DA depletion. J.Neurochem. 95 79 PMID: 16181414
If you know of a relevant reference for M 30 dihydrochloride, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: M 30 dihydrochloride, M 30 dihydrochloride supplier, M30, dihydrochloride, MAO, monoamine, oxidase, MAOA, MAOB, inhibitors, inhibits, non-selective, potent, antioxidant, iron, chelator, Monoamine, Oxidase, Antioxidants, Biochemicals, and, Molecular, Biology, 6067, Tocris Bioscience
Citations for M 30 dihydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for M 30 dihydrochloride. Do you know of a great paper that uses M 30 dihydrochloride from Tocris? Please let us know.
Reviews for M 30 dihydrochloride
There are currently no reviews for this product. Be the first to review M 30 dihydrochloride and earn rewards!
Have you used M 30 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.